Concepts (193)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Angioplasty, Balloon, Coronary | 17 | 2012 | 1873 | 2.480 |
Why?
|
| Myocardial Infarction | 33 | 2022 | 11727 | 1.750 |
Why?
|
| Acute Coronary Syndrome | 14 | 2022 | 2337 | 1.520 |
Why?
|
| Coronary Circulation | 12 | 2013 | 1572 | 1.520 |
Why?
|
| Platelet Aggregation Inhibitors | 20 | 2023 | 3068 | 1.370 |
Why?
|
| Thrombolytic Therapy | 9 | 2011 | 2161 | 1.210 |
Why?
|
| Morpholines | 3 | 2014 | 571 | 1.060 |
Why?
|
| Thiophenes | 3 | 2014 | 588 | 0.960 |
Why?
|
| Fibrinolytic Agents | 10 | 2021 | 2158 | 0.820 |
Why?
|
| Electrocardiography | 12 | 2014 | 6442 | 0.800 |
Why?
|
| Ticlopidine | 6 | 2017 | 899 | 0.730 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 9 | 2023 | 361 | 0.720 |
Why?
|
| Coronary Angiography | 14 | 2021 | 4577 | 0.690 |
Why?
|
| Aspirin | 10 | 2023 | 3282 | 0.670 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2014 | 585 | 0.630 |
Why?
|
| Stents | 6 | 2021 | 3280 | 0.610 |
Why?
|
| Hemorrhage | 8 | 2023 | 3461 | 0.530 |
Why?
|
| Intercostal Nerves | 1 | 2013 | 26 | 0.460 |
Why?
|
| Coronary Occlusion | 2 | 2014 | 304 | 0.460 |
Why?
|
| Drug Therapy, Combination | 13 | 2023 | 6489 | 0.450 |
Why?
|
| Myocardial Ischemia | 3 | 2016 | 2148 | 0.440 |
Why?
|
| No-Reflow Phenomenon | 1 | 2012 | 14 | 0.430 |
Why?
|
| Vitamin K | 1 | 2014 | 295 | 0.430 |
Why?
|
| Denervation | 1 | 2013 | 278 | 0.420 |
Why?
|
| Coronary Artery Disease | 5 | 2021 | 6487 | 0.420 |
Why?
|
| Adenosine | 2 | 2016 | 825 | 0.400 |
Why?
|
| Bilirubin | 1 | 2013 | 425 | 0.390 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2011 | 482 | 0.380 |
Why?
|
| Anticoagulants | 5 | 2021 | 4599 | 0.380 |
Why?
|
| Myocardial Reperfusion | 2 | 2002 | 351 | 0.380 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2010 | 641 | 0.370 |
Why?
|
| Atrial Fibrillation | 3 | 2021 | 5034 | 0.370 |
Why?
|
| Drug-Eluting Stents | 1 | 2017 | 753 | 0.360 |
Why?
|
| Polymers | 1 | 2017 | 1621 | 0.350 |
Why?
|
| Enoxaparin | 2 | 2008 | 377 | 0.330 |
Why?
|
| Cryosurgery | 1 | 2013 | 453 | 0.320 |
Why?
|
| Platelet Count | 2 | 2011 | 781 | 0.310 |
Why?
|
| Heptanoic Acids | 1 | 2009 | 343 | 0.310 |
Why?
|
| Pravastatin | 1 | 2009 | 395 | 0.300 |
Why?
|
| Coronary Thrombosis | 1 | 2011 | 495 | 0.300 |
Why?
|
| Adenosine Monophosphate | 2 | 2021 | 275 | 0.300 |
Why?
|
| Treatment Outcome | 25 | 2023 | 63114 | 0.290 |
Why?
|
| Hyperemia | 1 | 2008 | 225 | 0.290 |
Why?
|
| Peptides | 4 | 2010 | 4409 | 0.280 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 371 | 0.280 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 1738 | 0.280 |
Why?
|
| Hospital Mortality | 6 | 2012 | 5317 | 0.280 |
Why?
|
| Thrombectomy | 1 | 2011 | 680 | 0.270 |
Why?
|
| Uric Acid | 1 | 2011 | 766 | 0.260 |
Why?
|
| Thrombosis | 3 | 2021 | 2968 | 0.260 |
Why?
|
| Ventricular Fibrillation | 1 | 2008 | 538 | 0.260 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 1440 | 0.250 |
Why?
|
| Vascular Patency | 2 | 2005 | 886 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2268 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 12 | 2022 | 9959 | 0.240 |
Why?
|
| Lymphocytes | 1 | 2012 | 2617 | 0.240 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 49 | 0.230 |
Why?
|
| Pyrroles | 1 | 2009 | 1146 | 0.220 |
Why?
|
| Pulsatile Flow | 1 | 2004 | 332 | 0.220 |
Why?
|
| Registries | 4 | 2021 | 8089 | 0.220 |
Why?
|
| Middle Aged | 30 | 2021 | 213383 | 0.210 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2004 | 1261 | 0.200 |
Why?
|
| Coronary Stenosis | 2 | 2005 | 834 | 0.190 |
Why?
|
| Double-Blind Method | 8 | 2017 | 12026 | 0.190 |
Why?
|
| Heparin | 1 | 2008 | 1637 | 0.190 |
Why?
|
| Emergency Medical Services | 2 | 2011 | 1917 | 0.190 |
Why?
|
| Humans | 54 | 2023 | 744343 | 0.180 |
Why?
|
| Creatine Kinase | 1 | 2002 | 694 | 0.180 |
Why?
|
| Ischemia | 1 | 2008 | 1907 | 0.180 |
Why?
|
| Male | 31 | 2021 | 350118 | 0.180 |
Why?
|
| Neutrophils | 1 | 2012 | 3719 | 0.170 |
Why?
|
| Blood Platelets | 1 | 2010 | 2508 | 0.170 |
Why?
|
| Tachycardia, Ventricular | 1 | 2008 | 1273 | 0.170 |
Why?
|
| Antithrombins | 3 | 2016 | 304 | 0.170 |
Why?
|
| Female | 31 | 2021 | 380194 | 0.170 |
Why?
|
| Aged | 22 | 2021 | 163280 | 0.160 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 2282 | 0.160 |
Why?
|
| Tyrosine | 1 | 2002 | 1461 | 0.150 |
Why?
|
| Postoperative Hemorrhage | 1 | 2021 | 413 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2021 | 39050 | 0.150 |
Why?
|
| Isoenzymes | 1 | 2002 | 1726 | 0.140 |
Why?
|
| Prospective Studies | 7 | 2016 | 53288 | 0.140 |
Why?
|
| Antibodies, Monoclonal | 2 | 2011 | 9274 | 0.130 |
Why?
|
| Secondary Prevention | 4 | 2016 | 1530 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 10943 | 0.120 |
Why?
|
| Postoperative Complications | 2 | 2017 | 15295 | 0.120 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2009 | 3255 | 0.120 |
Why?
|
| Coronary Disease | 2 | 2013 | 6077 | 0.110 |
Why?
|
| Prognosis | 6 | 2021 | 29063 | 0.110 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2014 | 629 | 0.100 |
Why?
|
| Angina, Unstable | 2 | 2008 | 926 | 0.100 |
Why?
|
| Turkey | 1 | 2011 | 237 | 0.100 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2011 | 234 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2017 | 3913 | 0.090 |
Why?
|
| Transportation of Patients | 1 | 2011 | 185 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2002 | 3107 | 0.090 |
Why?
|
| Injections, Intra-Arterial | 1 | 2010 | 193 | 0.090 |
Why?
|
| Hirudins | 1 | 2011 | 183 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2012 | 3778 | 0.090 |
Why?
|
| Lymphocyte Count | 1 | 2012 | 793 | 0.090 |
Why?
|
| Risk Assessment | 4 | 2021 | 23338 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 12245 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2214 | 0.080 |
Why?
|
| Time and Motion Studies | 1 | 2008 | 149 | 0.080 |
Why?
|
| Time Factors | 7 | 2021 | 40075 | 0.080 |
Why?
|
| Drug Dosage Calculations | 1 | 2008 | 114 | 0.080 |
Why?
|
| Blood Flow Velocity | 2 | 2002 | 1423 | 0.080 |
Why?
|
| Endpoint Determination | 1 | 2011 | 601 | 0.080 |
Why?
|
| Contrast Media | 1 | 2001 | 5300 | 0.080 |
Why?
|
| Injections, Intravenous | 1 | 2010 | 1420 | 0.080 |
Why?
|
| Drug Administration Schedule | 2 | 2008 | 4933 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2013 | 783 | 0.070 |
Why?
|
| Neuralgia | 1 | 2013 | 570 | 0.070 |
Why?
|
| Nerve Block | 1 | 2013 | 644 | 0.070 |
Why?
|
| Survival Rate | 3 | 2017 | 12788 | 0.070 |
Why?
|
| Embolism | 1 | 2010 | 408 | 0.070 |
Why?
|
| Statistics, Nonparametric | 2 | 2002 | 2886 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2012 | 2971 | 0.070 |
Why?
|
| Comorbidity | 2 | 2012 | 10388 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2013 | 1486 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2011 | 10252 | 0.060 |
Why?
|
| Incidence | 4 | 2021 | 20947 | 0.060 |
Why?
|
| Regional Blood Flow | 1 | 2008 | 1525 | 0.060 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2011 | 964 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 2274 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2009 | 15165 | 0.060 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 695 | 0.060 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 209 | 0.060 |
Why?
|
| Coronary Artery Bypass | 2 | 2022 | 2289 | 0.060 |
Why?
|
| Adult | 7 | 2016 | 214055 | 0.060 |
Why?
|
| Recurrence | 2 | 2006 | 8340 | 0.060 |
Why?
|
| Stroke | 2 | 2022 | 9981 | 0.050 |
Why?
|
| Medicare | 1 | 2021 | 6566 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2013 | 2266 | 0.050 |
Why?
|
| Atherectomy | 1 | 2002 | 47 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2012 | 6459 | 0.050 |
Why?
|
| Cardiology | 1 | 2013 | 1668 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 85781 | 0.050 |
Why?
|
| Creatine Kinase, MB Form | 1 | 2002 | 214 | 0.050 |
Why?
|
| Pyridines | 1 | 2013 | 2825 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2002 | 287 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2013 | 3743 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6622 | 0.050 |
Why?
|
| Retrospective Studies | 4 | 2014 | 77449 | 0.050 |
Why?
|
| Echocardiography | 1 | 2013 | 5102 | 0.050 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2001 | 341 | 0.040 |
Why?
|
| Exercise Test | 1 | 2007 | 2074 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2014 | 12959 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2004 | 1240 | 0.040 |
Why?
|
| Patient Selection | 1 | 2011 | 4215 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2011 | 5097 | 0.040 |
Why?
|
| Fishes | 1 | 2021 | 569 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 2003 | 996 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 6895 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2004 | 1518 | 0.040 |
Why?
|
| Pericardium | 1 | 2002 | 667 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2373 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 56430 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6538 | 0.040 |
Why?
|
| United States | 4 | 2021 | 69872 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2008 | 8642 | 0.030 |
Why?
|
| History, Ancient | 1 | 2016 | 212 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2002 | 3508 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 15076 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 7279 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2021 | 1681 | 0.030 |
Why?
|
| Risk Factors | 4 | 2013 | 72290 | 0.030 |
Why?
|
| Research Design | 1 | 2011 | 5987 | 0.030 |
Why?
|
| Equipment Design | 1 | 2003 | 3582 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 1917 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2008 | 12354 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2002 | 6365 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2016 | 3610 | 0.030 |
Why?
|
| Heart Rate | 1 | 2004 | 4091 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 5751 | 0.030 |
Why?
|
| Drug Delivery Systems | 1 | 2003 | 2219 | 0.030 |
Why?
|
| Linear Models | 1 | 2002 | 5952 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15540 | 0.020 |
Why?
|
| History, 21st Century | 1 | 2016 | 1534 | 0.020 |
Why?
|
| Mortality | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 40561 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2016 | 2740 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2001 | 5007 | 0.020 |
Why?
|
| Hospitals | 1 | 2021 | 3952 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 1420 | 0.020 |
Why?
|
| Cause of Death | 1 | 2017 | 3584 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2013 | 1504 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2013 | 1547 | 0.020 |
Why?
|
| Heart Failure | 1 | 2008 | 10900 | 0.020 |
Why?
|
| Consensus | 1 | 2013 | 2959 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13408 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 57776 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 168757 | 0.010 |
Why?
|
Concepts
(193)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(18)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_